RESUMEN
Spontaneous intracranial hemorrhage (ICH) remains a devastating stroke subtype, affecting as many as 80,000 people annually in the United States and associated with extremely high mortality. In the absence of any pharmacological interventions demonstrated to improve outcome, care for patients with ICH remains largely supportive. Thus, despite advances in the understanding of ICH and brain injury, there remains an unmet need for interventions that improve neurologic recovery and outcomes. Recent research suggesting inflammation and APOE genotype play a role in modifying neurologic outcome after brain injury has led to the development of an APOE-derived peptide agent (CN-105). Preclinical studies have demonstrated that CN-105 effectively downregulates the inflammatory response in acute brain injury, including ICH. Following Investigational New Drug (IND) enabling studies in murine models, this first-in-human single escalating dose and multiple dose placebo-controlled clinical trial was performed to define the safety and pharmacokinetics (PK) of CN-105. A total of 48 subjects (12 control, 36 active) were randomized in this study; all subjects completed the study. No significant safety issues were identified with both dosing regimens, and PK analysis revealed linearity without significant drug accumulation. The median half-life in the terminal elimination phase of CN-105 following a single or repeated dosing regimen did not change (approximately 3.6 hours). With the PK and preliminary safety of CN-105 established, the drug is now poised to begin first-in-disease phase 2 clinical trials in patients with ICH who urgently need new therapeutic options.
Asunto(s)
Antiinflamatorios/farmacocinética , Fármacos Neuroprotectores/farmacocinética , Adulto , Antiinflamatorios/efectos adversos , Antiinflamatorios/sangre , Antiinflamatorios/orina , Método Doble Ciego , Femenino , Voluntarios Sanos , Humanos , Masculino , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orinaRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Pinocembrin is the most abundant flavonoid in propolis. Preclinical studies have suggested that pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro. To investigate the safety, tolerability and pharmacokinetics of a new neuroprotective agent, pinocembrin. MATERIALS AND METHOD: A double-blind, placebo-controlled, randomized study was carried out in 58 healthy subjects. Single ascending doses of pinocembrin (20-150 mg) were evaluated in 5 cohorts. Multi-dose was studied at pinocembrin 60 mg. RESULTS: Pinocembrin was well tolerated. No serious adverse events occurred. No subjects were discontinued because of a treatment emergent AE. Treatment related adverse event was acute urticaria. Two subjects in 150 mg cohort developed grade II urticaria during the study. One subject discontinued after 3 days at 60 mg bid because of diarrhea. In the single-dose study, the mean peak plasma pinocembrin concentration was obtained at the end of the 30-min infusion. The Cmax ranged from 0.28 µg mL(-1) to 2.46 µg mL(-1). AUC (0,∞) ranged from 10.34 µg mL(-1) min to 89.34 µg mL(-1) min. The T1/2 was similar across 5 dose groups, ranging from 40 to 55 min. Both urinary and feces excretion levels of pinocembrin were extremely low and similar among each dose groups, with mean values ranging from 0.07% to 0.17% and 0.94% to 1.94% of the administered dose, respectively. Linear increases in Cmax and AUC(0,∞) were observed. The pharmacokinetics of pinocembrin in multiple-dose was similar to those observed in the single-dose study, with no evidence of accumulation. Both urinary and feces excretion levels of pinocembrin were extremely low. CONCLUSIONS: Pinocembrin displayed linear plasma pharmacokinetics over the dose range, 20-150 mg and was well tolerated up to 120 mg day(-1) when administered intravenously to healthy adults. No major safety concerns were identified that would preclude further clinical development of pinocembrin injection.
Asunto(s)
Flavanonas/farmacocinética , Fármacos Neuroprotectores/farmacocinética , Administración Intravenosa , Adulto , Método Doble Ciego , Heces/química , Femenino , Flavanonas/efectos adversos , Flavanonas/sangre , Flavanonas/orina , Humanos , Masculino , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orina , Adulto JovenRESUMEN
Isorhynchophylline is one of the major alkaloids from the Uncaria hook possessing the effects of lowered blood pressure, vasodilatation and protection against ischemia-induced neuronal damage. However, the metabolic pathway of isorhynchophylline has not been fully reported yet. In this paper, the metabolism of isorhynchophylline was investigated in rats. Five metabolites were isolated by using solvent extraction and repeated chromatographic methods, and identified by spectroscopic methods including UV, MS, NMR and CD experiments. Three new compounds were identified as 5-oxoisorhynchophyllic acid-22-O-ß-D-glucuronide (M1), 17-O-demethyl-16,17-dihydro isorhynchophylline (M2) and 5-oxoisorhynchophyllic acid (M4) together with two known compounds isorhynchophylline (M0) and rhynchophylline (M3). Possible metabolic pathways of isorhynchophylline are proposed. Furthermore, the activity assay for all the metabolites showed that isorhynchophylline (M0) exhibited potent neuroprotective effects against glutamate-induced HT22 cell death. However, little or weak neuroprotective activities were observed for M1-M4. Our present study is important to further understand its metabolic fate and disposition in humans.
Asunto(s)
Hipocampo/efectos de los fármacos , Alcaloides Indólicos/orina , Fármacos Neuroprotectores/orina , Animales , Muerte Celular/efectos de los fármacos , Línea Celular , Ácido Glutámico , Alcaloides Indólicos/farmacología , Masculino , Ratones , Estructura Molecular , Fármacos Neuroprotectores/farmacología , Oxindoles , Ratas WistarRESUMEN
This phase I, open-label, single-dose study evaluated the pharmacokinetics, safety, and tolerability of renally excreted drug dexpramipexole in subjects with normal and impaired renal function, i.e. mild, moderate, severe renal impairment, or end-stage renal disease (ESRD) requiring hemodialysis when matched by age and sex. Dexpramipexole area under the curves (AUCs), but not Cmax , were significantly increased with the severity of renal impairment after a single dose administration. The geometric mean ratio of dose-normalized AUC(0-72) was 1.4, 1.7, 2.7, and 4.5, respectively, in mild, moderate, severe renal impairment, and ESRD subjects when compared to healthy subjects. There was a strong association between renal function (eGFR) and dexpramipexole CLr. The slope (90% confidence interval(CI)) of eGFR and renal clearance (CLr) in the regression model was 3.1 (2.4, 3.7). Dexpramipexole elimination in ESRD subjects during both dialysis and non-dialysis (i.e., interval between dialysis) was insignificant. Single 75 mg and 150 mg doses of dexpramipexole were well tolerated, and the safety profile was comparable across renal function groups. Extensive drug accumulation may occur with repeated dosing in patients with significant renal impairment. It is recommended that dexpramipexole not to be given to patients with severe renal impairment or in those with ESRD.
Asunto(s)
Benzotiazoles/farmacocinética , Fármacos Neuroprotectores/farmacocinética , Insuficiencia Renal/metabolismo , Adulto , Anciano , Benzotiazoles/sangre , Benzotiazoles/orina , Femenino , Tasa de Filtración Glomerular , Humanos , Masculino , Persona de Mediana Edad , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orina , Pramipexol , Insuficiencia Renal/fisiopatologíaRESUMEN
BACKGROUND: High-dose recombinant human erythropoietin (rEpo) has first been administered in clinical trials for neuroprotection in very preterm neonates at high risk of brain injury and in (near-) term neonates with hypoxic-ischemic encephalopathy. However, recent trials in adults raised concerns about the safety of high-dose rEpo for neuro- and cardioprotection. OBJECTIVES: To evaluate the putative accumulation or renal leakage of Epo as a function of developmental stage after repetitive early short-term infusion of high-dose rEpo (3 × 3,000 U/kg within 42 h after birth; NCT00413946) for neuroprotection in very preterm infants. METHODS: Epo concentrations were measured using the ELISA technique in the first two consecutive urine specimens after each rEpo infusion. RESULTS: Renal Epo excretion was significantly higher in preterm infants with gestational ages <29 weeks than in more mature infants and reached up to 23% of the administered rEpo within 8 h after each infusion. The urinary Epo concentration did not increase after three repetitive infusions of high-dose rEpo. The ratio of urinary Epo to total protein concentrations was the same in infants with gestational ages <29 weeks and in those with gestational ages ≥29 weeks. CONCLUSIONS: Our data suggest that the higher renal Epo excretion in more immature infants may be attributed to a higher glomerular filtration leakage due to the lower maturation of the kidneys and argue against saturation kinetics after multiple doses of 3,000 U/kg rEpo. This information should be considered in future trials on the use of rEpo for neuroprotection in neonates.
Asunto(s)
Anemia Neonatal/prevención & control , Citoprotección/efectos de los fármacos , Eritropoyetina/administración & dosificación , Eritropoyetina/orina , Recien Nacido Prematuro , Neuronas/efectos de los fármacos , Anemia Neonatal/metabolismo , Anemia Neonatal/orina , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Eritropoyetina/farmacología , Femenino , Humanos , Hipoxia-Isquemia Encefálica/metabolismo , Hipoxia-Isquemia Encefálica/prevención & control , Hipoxia-Isquemia Encefálica/orina , Recién Nacido , Recien Nacido Prematuro/fisiología , Recien Nacido Prematuro/psicología , Bombas de Infusión , Masculino , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/farmacocinética , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/orina , Concentración Osmolar , Placebos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/orina , Factores de TiempoRESUMEN
Insulin resistance is implicated in the pathophysiological changes associated with Alzheimer's disease, and pharmaceutical treatments that overcome insulin resistance improve memory function in subjects with mild cognitive impairment (MCI) and early Alzheimer's disease. Chromium (Cr) supplementation improves glucose disposal in patients with insulin resistance and diabetes. We sought to assess whether supplementation with Cr might improve memory and neural function in older adults with cognitive decline. In a placebo-controlled, double-blind trial, we randomly assigned 26 older adults to receive either chromium picolinate (CrPic) or placebo for 12 weeks. Memory and depression were assessed prior to treatment initiation and during the final week of treatment. We also performed functional magnetic resonance imaging (fMRI) scans on a subset of subjects. Although learning rate and retention were not enhanced by CrPic supplementation, we observed reduced semantic interference on learning, recall, and recognition memory tasks. In addition, fMRI indicated comparatively increased activation for the CrPic subjects in right thalamic, right temporal, right posterior parietal, and bifrontal regions. These findings suggest that supplementation with CrPic can enhance cognitive inhibitory control and cerebral function in older adults at risk for neurodegeneration.
Asunto(s)
Cromo/uso terapéutico , Cognición , Demencia/prevención & control , Suplementos Dietéticos , Trastornos de la Memoria/prevención & control , Memoria , Fármacos Neuroprotectores/uso terapéutico , Anciano , Glucemia/análisis , Encéfalo/metabolismo , Cromo/orina , Demencia/sangre , Demencia/metabolismo , Demencia/orina , Depresión/prevención & control , Método Doble Ciego , Femenino , Humanos , Aprendizaje , Masculino , Trastornos de la Memoria/sangre , Trastornos de la Memoria/metabolismo , Trastornos de la Memoria/orina , Recuerdo Mental , Enfermedades Neurodegenerativas/prevención & control , Fármacos Neuroprotectores/orina , Ácidos Picolínicos/administración & dosificación , Reconocimiento en Psicología , Retención en PsicologíaRESUMEN
The purpose of this study is to investigate the possible mechanism and the neuroprotective effect of human urinary kallidinogenase (HUK) in cerebral ischemia. The mouse middle cerebral artery occlusion (MCAO) model was used. Mice were treated with HUK (20 PNAU/g per day, intravenous) or saline as control, from the beginning of reperfusion to 72 h. Neurological deficits, infarct size, and BWC were measured at 6, 24, 48, and 72 h after MCAO, respectively. Pathological changes of brain were observed by TUNEL assay. Inflammatory factors were measured by real-time PCR and western blotting. Activation of MAPKs, Akt, and nuclear factor-kappaB (NF-kappaB) was detected by western blotting. Our results indicated that HUK significantly improved neurofunction, decreased infarct size, and suppressed edema, as well as inflammatory mediators as compared with the vehicle group. Furthermore, HUK inhibited the NF-kappaB pathway and activated the MAPK/ERK pathway in this neuroprotection.
Asunto(s)
Isquemia Encefálica , Coagulantes , Inflamación , Calicreínas , FN-kappa B/metabolismo , Fármacos Neuroprotectores , Accidente Cerebrovascular , Animales , Conducta/fisiología , Biomarcadores/metabolismo , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patología , Coagulantes/uso terapéutico , Coagulantes/orina , Activación Enzimática , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Femenino , Humanos , Etiquetado Corte-Fin in Situ , Infarto de la Arteria Cerebral Media/patología , Inflamación/tratamiento farmacológico , Inflamación/patología , Calicreínas/uso terapéutico , Calicreínas/orina , Masculino , Ratones , Fármacos Neuroprotectores/uso terapéutico , Fármacos Neuroprotectores/orina , Pruebas Neuropsicológicas , Transducción de Señal/fisiología , Accidente Cerebrovascular/tratamiento farmacológico , Accidente Cerebrovascular/metabolismo , Accidente Cerebrovascular/patologíaRESUMEN
Modafinil has been reported to reduce cocaine use in a clinical sample of infrequent users (2 days/week), but the effects of modafinil on cocaine self-administration in the laboratory have not been studied. The present study investigated the effects of modafinil maintenance on cocaine self-administration by frequent users (4 days/week) under controlled laboratory conditions. During this 48-day double-blind, crossover design study, the effects of modafinil maintenance (0, 200, and 400 mg/day) on response to smoked cocaine (0, 12, 25, and 50 mg) were examined in nontreatment-seeking cocaine-dependent individuals (n=8). Cocaine significantly increased self-administration, subjective-effect ratings, and cardiovascular measures; modafinil at both doses (200 and 400 mg/day) markedly attenuated these effects. These findings agree with data from previous human laboratory and clinical investigations of modafinil as a potential cocaine abuse treatment medication. Thus, our data support the potential of modafinil as a pharmacotherapy for cocaine dependence.
Asunto(s)
Compuestos de Bencidrilo/uso terapéutico , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Trastornos Relacionados con Cocaína/psicología , Cocaína/administración & dosificación , Inhibidores de Captación de Dopamina/administración & dosificación , Fármacos Neuroprotectores/uso terapéutico , Adulto , Compuestos de Bencidrilo/sangre , Compuestos de Bencidrilo/orina , Presión Sanguínea/efectos de los fármacos , Cocaína/sangre , Estudios Cruzados , Inhibidores de Captación de Dopamina/sangre , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Modafinilo , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orina , Dimensión del Dolor , Autoadministración/métodos , Encuestas y Cuestionarios , Factores de TiempoAsunto(s)
Bencenosulfonatos/farmacocinética , Fármacos Neuroprotectores/farmacocinética , Transportadores de Anión Orgánico/fisiología , Adulto , Bencenosulfonatos/efectos adversos , Bencenosulfonatos/sangre , Bencenosulfonatos/orina , Cimetidina/farmacología , Interacciones Farmacológicas , Femenino , Tasa de Filtración Glomerular , Humanos , Inulina , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orina , Transportadores de Anión Orgánico/antagonistas & inhibidores , Probenecid/farmacologíaRESUMEN
OBJECTIVE: NXY-059 is a novel free-radical trapping neuroprotectant. Digoxin treatment is common in acute ischaemic stroke, the intended patient population for NXY-059. Since both digoxin and NXY-059 are eliminated primarily renally, with a substantial contribution by active renal secretion, and because digoxin has a narrow therapeutic window, this open, randomised, crossover, two-period study investigated whether NXY-059 affects the pharmacokinetics (PK) of digoxin. RESEARCH DESIGN AND METHODS: Twenty-two healthy subjects received 0.5 mg oral digoxin 2 h after the start of 60-h intravenous infusions of NXY-059 and placebo separated by a 14-day washout. Blood and urine were collected for 60 h. Digoxin concentrations were measured by a novel liquid chromatography-mass spectrometry assay. MAIN OUTCOME MEASURES: The ratio of the geometric mean (90% confidence interval) between NXY-059 and placebo for the digoxin area under the concentration-versus-time curve was 0.91 (0.83-0.99) and was within the predefined range for no interaction (0.80-1.25). No safety concerns were raised in the study. No serious adverse events were recorded. The most common adverse event was headache with similar frequencies in the two treatments. CONCLUSIONS: NXY-059 had no clinically significant effect on the PK of digoxin.
Asunto(s)
Antiarrítmicos/farmacocinética , Bencenosulfonatos/administración & dosificación , Digoxina/farmacocinética , Fármacos Neuroprotectores/administración & dosificación , Adolescente , Adulto , Antiarrítmicos/sangre , Antiarrítmicos/orina , Bencenosulfonatos/sangre , Bencenosulfonatos/orina , Cromatografía Liquida/métodos , Digoxina/sangre , Digoxina/orina , Femenino , Humanos , Masculino , Espectrometría de Masas/métodos , Persona de Mediana Edad , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orinaRESUMEN
AIM: To study the excretion of (-)-clausenamide in rats. METHODS: The urine, feces and bile were collected at predetermined time points after (-)-clausenamide was orally administrated to 6 rats (30 mg x kg(-1)). The concentrations of (-)-clausenamide and its metabolite 6-OH-(-)-clausnamide were determined by HPLC-MS/MS method using glipzide as the internal reference, and the accumulative excretion amount of (-)-clausenamide and 6-OH-(-)-clausenamide was calculated in the urine, feces and bile, separately. RESULTS: (-)-Clausenamide was recovered mostly (44%) from feces in 112 hours, 7.1% was found from urine in 120 hours and 0.013% was detected from bile in 24 hours. The accumulative excretions of 6-OH-(-)-clausenamide were 0.92% , 0.46% and 0.0003% of the administered dose from feces, urine and bile, respectively. CONCLUSION: The major amount of (-)-clausenamide was recovered from feces after (-)-clausenamide was orally administrated to rats (30 mg kg(-1)).
Asunto(s)
Bilis/metabolismo , Clausena/química , Heces/química , Lactamas/farmacocinética , Lignanos/farmacocinética , Administración Oral , Animales , Cromatografía Líquida de Alta Presión , Femenino , Lactamas/química , Lactamas/orina , Lignanos/química , Lignanos/orina , Masculino , Espectrometría de Masas , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/farmacocinética , Fármacos Neuroprotectores/orina , Hojas de la Planta/química , Plantas Medicinales/química , Ratas , Ratas Sprague-Dawley , EstereoisomerismoRESUMEN
Studies were conducted to characterize the pharmacokinetics and excretion of hydroxysafflor yellow A (HSYA) in rats and dogs after administration by intravenous injection or infusion. Plasma, urine, feces and bile concentrations of HSYA were measured using five validated mild HPLC methods. Linear pharmacokinetics of HSYA after the intravenous administrations were found at doses ranging from 3 to 24 mg/kg in rats and from 6 to 24 mg/kg in dogs. At a dose of 3 mg/kg, HSYA in urine, feces and bile was determined. For 48 h after dosing, the amount of urinary excretion accounted for 52.6 +/- 17.9 % (range: 31.1 - 78.7%, n = 6) of the dose, and the amount of fecal amount accounted for 8.4 +/- 5.3% (range 1.7 - 16.4%, n = 6) of the dose. Biliary excretion amount accounted for 1.4 +/- 1.0% (range 0.4-2.9%; n = 6) of the dose for 24 h after dosing. Percent plasma protein binding of HSYA ranged from 48.0 to 54.6% at 72 h. In summary, five mild HPLC methods for the determinations of HSYA in rat plasma, urine, feces, bile and dog plasma have been developed and successfully applied to preclinical pharmacokinetics and excretion of HSYA in rats and dogs. The results of excretion studies indicated that HSYA was rapidly excreted as unchanged drug in the urine. In view of previous pharmacological work, the concentration-dependent neuroprotective effect of HSYA in rats was defined.
Asunto(s)
Carthamus tinctorius , Chalcona/análogos & derivados , Fármacos Neuroprotectores/farmacocinética , Fitoterapia , Pigmentos Biológicos/farmacocinética , Quinonas/farmacocinética , Animales , Área Bajo la Curva , Bilis/metabolismo , Chalcona/administración & dosificación , Chalcona/sangre , Chalcona/química , Chalcona/farmacocinética , Chalcona/orina , Perros , Heces/química , Infusiones Intravenosas , Inyecciones Intravenosas , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/orina , Pigmentos Biológicos/administración & dosificación , Pigmentos Biológicos/sangre , Pigmentos Biológicos/química , Pigmentos Biológicos/orina , Extractos Vegetales/administración & dosificación , Extractos Vegetales/sangre , Extractos Vegetales/química , Extractos Vegetales/farmacocinética , Extractos Vegetales/orina , Unión Proteica/efectos de los fármacos , Quinonas/administración & dosificación , Quinonas/sangre , Quinonas/química , Quinonas/orina , Ratas , Ratas Sprague-DawleyRESUMEN
INTRODUCTION: Positron emission tomography (PET) is a useful tool for the investigation of certain physiological changes and for the evaluation of the distribution, and receptor binding of drugs labelled with positron emitting isotopes. Vinpocetine (ethyl-apovincaminate) is a neuroprotective drug widely used in the prevention and treatment of cerebrovascular diseases. In the clinical practice vinpocetine is usually administered to the patients in intravenous infusion followed by long-term oral treatment. Until presently human data describing vinpocetine's kinetics and brain distribution came from ex vivo (blood, plasma, liquor) and post mortem (brain autoradiography) measurements. AIM: The authors wished to investigate the kinetics and distribution of vinpocetine in the brain and body after oral administration with PET in order to prove, that PET is useful in the non-invasive in vivo determination of these parameters. METHOD: Vinpocetine was labelled with carbon-11 and the radioactivity was measured by PET in the stomach, liver, brain, colon and kidneys in healthy male volunteers. The radioactivity in the blood and urine was also determined. RESULTS: After oral administration, [11C]vinpocetine appeared immediately in the stomach and within minutes in the liver and the blood. In the blood the level of radioactivity continuously increased until the end of the measurement period, whereas the fraction of the unchanged mother compound decreased. Radioactivity uptake and distribution in the brain were demonstrable from the tenth minute after the oral administration of the labelled drug (average maximum uptake: 0.7% of the administered total dose). Brain distribution was heterogeneous (with preferences in the thalamus, basal ganglia and occipital cortex), similar to the distribution previously reported by the authors after intravenous administration. CONCLUSIONS: Vinpocetine, administered orally to human volunteers, readily entered the bloodstream from the stomach and the gastrointestinal tract and thereafter passed the blood-brain barrier and entered the brain. Radioactivity from [11C]vinpocetine was also demonstrated in the kidneys and in urine. The study demonstrates that PET might be a useful, direct and non-invasive tool to study the distribution and pharmacokinetics of orally administered labelled drugs active in the central nervous system in the living human body.
Asunto(s)
Encéfalo/metabolismo , Radioisótopos de Carbono , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/farmacocinética , Tomografía Computarizada de Emisión/métodos , Alcaloides de la Vinca/administración & dosificación , Alcaloides de la Vinca/farmacocinética , Administración Oral , Adulto , Encéfalo/diagnóstico por imagen , Radioisótopos de Carbono/administración & dosificación , Mucosa Gástrica/metabolismo , Humanos , Riñón/metabolismo , Hígado/metabolismo , Masculino , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orina , Valores de Referencia , Factores de Tiempo , Distribución Tisular , Alcaloides de la Vinca/sangre , Alcaloides de la Vinca/orinaRESUMEN
Very little is known regarding melatonin's circadian rhythm in stroke patients. We compared urinary-sulfatoxymelatonin (6-SMT), its major metabolite, in 11 extensive cortical and seven deep or lacunar stroke patients on day 3 or 4 and day 10 post-stroke. Urinary 6-SMT and creatinine measured every 4 h for 24 h starting at 06:00 h significantly fluctuated during the day in both types of stroke and did not differ between day 3 or 4 and day 10 post-stroke. However, in extensive cortical lesions, a delay in the 6-SMT excretion was observed in the first post-stroke days compared to day 10. We conclude that circadian oscillator is preserved in extensive cortical as well as in deep and lacunar strokes. Extensive cortical stroke might delay the melatonin surge during the first post-stroke days.
Asunto(s)
Encéfalo/fisiopatología , Ritmo Circadiano/fisiología , Melatonina/análogos & derivados , Melatonina/orina , Accidente Cerebrovascular/fisiopatología , Accidente Cerebrovascular/orina , Factores de Edad , Anciano , Encéfalo/patología , Supervivencia Celular/fisiología , Femenino , Humanos , Masculino , Melatonina/metabolismo , Fármacos Neuroprotectores/orina , Radioinmunoensayo , Factores Sexuales , Accidente Cerebrovascular/patologíaRESUMEN
A high-performance liquid chromatographic method was developed for the determination of a neuroprotective agent for ischemia-reperfusion damage, KR-31378, in human plasma and urine and in rat tissue homogenates. The method involved deproteinization of the the biological samples with 0.5 volumes of saturated Ba(OH)2, 0.5 volumes of 0.04 M ZnSO4 and 1 volume of acetonitrile. A 80-microl aliqout of the supernatant was injected onto a reversed-phase C18 column. The mobile phase, 50 mM triethylamine acetate : acetonitrile : tetrahydrofuran (65:30:5, v/v/v), was run at a flow rate of 1.0 ml/min. The column effluent was mornitored by a ultraviolet detector set at 310 nm. The retention time of KR-31378 was approximately 6.5 min. The detection limits of KR-31378 in human plasma and urine and rat tissue homogenates were 0.2, 0.5 and 0.5 microg/ml, respectively. The coefficients of variation (within-day and between-day) were below 13.6% for human plasma and urine and rat homogenates. No interferences from endogenous substances were found.
Asunto(s)
Guanidinas/análisis , Fármacos Neuroprotectores/análisis , Piranos/análisis , Daño por Reperfusión/tratamiento farmacológico , Animales , Cromatografía Líquida de Alta Presión , Guanidinas/sangre , Guanidinas/orina , Humanos , Indicadores y Reactivos , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/orina , Piranos/sangre , Piranos/orina , Ratas , Ratas Sprague-Dawley , Estándares de Referencia , Espectrofotometría Ultravioleta , Distribución TisularRESUMEN
The styryl alpha-pyrones, d-kawain (1) and d-methysticin (2) are two of the major kavalactone constituents of the anxiolvtic herb Piper methysticum, commonly known as kava. The use of fungal models to mimic the mammalian metabolism of 1 resulted in the production of 4'-hydroxykawain (1a) from the culture broth of Cunninghamella elegans (ATCC 9245), the same metabolite identified in rat urine. The fungus Torulopsis petrophilum (ATCC 20225) biotransformed 2 to 3'-hydroxy-4'-methoxykawain (2c) which is analogous, but not identical, to a known rat metabolite of methysticin.
Asunto(s)
Cunninghamella/metabolismo , Piranos/metabolismo , Pironas/metabolismo , Animales , Ansiolíticos/metabolismo , Ansiolíticos/orina , Biotransformación , Fármacos Neuroprotectores/metabolismo , Fármacos Neuroprotectores/orina , Piranos/orina , Pironas/orina , RatasRESUMEN
The metabolism and urinary elimination of both (-)-deprenyl and (+)-deprenyl have been studied. Gas-chromatographic analysis with mass specific detection indicated that the metabolism of (-)-deprenyl results in a large excess of methamphetamine compared to amphetamine, while the metabolism of (+)-deprenyl gave nearly equal amounts of amphetamine and methamphetamine. A novel deprenyl metabolite, phenylacetone, was also identified in our studies.
Asunto(s)
Cromatografía de Gases y Espectrometría de Masas/métodos , Inhibidores de la Monoaminooxidasa/farmacocinética , Fármacos Neuroprotectores/farmacocinética , Selegilina/farmacocinética , Anfetamina/orina , Humanos , Masculino , Metanfetamina/orina , Inhibidores de la Monoaminooxidasa/química , Inhibidores de la Monoaminooxidasa/orina , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/orina , Selegilina/química , Selegilina/orina , EstereoisomerismoRESUMEN
A reverse-phase High Performance Liquid Chromatographic (HPLC) method was developed for the analysis of metoprolol in the large number of human plasma samples obtained in in vitro-in vivo correlations (IVIVC) and bioavailability studies of extended release formulations of metoprolol tartrate. The metabolite, alpha-hydroxy metoprolol (OH-met), could also be quantified. The analytes were extracted from the plasma using solid phase columns, separated on a C-4 analytical column followed by fluorimetric detection. The linearity, precision, accuracy, stability, selectivity and ruggedness were validated for the concentration ranges of 1-400 ng ml-1 for metoprolol and 0.5-200 ng ml-1 for OH-met. The same chromatographic conditions were slightly modified to quantify dextromethorphan and its metabolite dextrorphan in urine in the concentration range 0.052-0.05 microgram ml-1 as a method for screening for fast metabolizers.
Asunto(s)
Antagonistas Adrenérgicos beta/sangre , Antitusígenos/orina , Dextrometorfano/orina , Dextrorfano/orina , Metoprolol/análogos & derivados , Fármacos Neuroprotectores/orina , Cromatografía Líquida de Alta Presión , Humanos , Indicadores y Reactivos , Metoprolol/sangre , Control de Calidad , Estándares de Referencia , Reproducibilidad de los Resultados , Espectrometría de FluorescenciaRESUMEN
The metabolites of dl-3-n-butylphthalide(NBP), a novel drug with promising protective action against cerebral ischemia, was studied in rats. Two main in vitro metabolites of NBP, M I and M II, were isolated and purified from rat liver microsome incubating system by using HPLC. The structure elucidation was mainly accomplished by spectral studies(UV, 1H-NMR, MS). Within 24 h following i.g. 3H-NBP, the total radioactivity excreted in urine and feces was 73.7% of the dose. Comparing with previous study, within 72 h following i.g. NBP, the total prototype drug excreted in urine and feces was 2.53% of the dose. This result excludes the possibility that NBP accumulates in vivo. The urine and brain homogenate of the rats(i.g. 3H-NBP) were analyzed by TLC. M I and M II were found in urine and M I was found in brain only. Furthermore, the ratio of radioactive M I to proptype drug was 1:1 in rat brain within 1 h following i.g. 3H-NBP. So, M I and M II were supposed to be the two main in vivo metabolites of NBP and M I might be an active metabolite.